| 764498 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
636 Patient-reported distress with immunotherapy-based first-line treatment for mNSCLC: a real-world evidence study |
2021-11-01 |
10.1136/jitc-2021-sitc2021.636 |
Bodd Monica, Locke Susan, Antonia Scott, Crawford Jeffrey, Hartman John, Herring Kris, Ready Neal, Stinchcombe Thomas, Troy Jesse, Williams Chakita, Wolf Steven, Clarke Jeffrey, LeBlanc Thomas |
| 764497 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
635 Online CME improves the interprofessional team's ability to manage patients with malignant pleural mesothelioma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.635 |
Worst Michelle, Laar Emily Van, Whitney Megan, Tsao Anne, Borghaei Hossein |
| 764496 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
632 Toripalimab combined with platinum-based chemotherapy as a second-line treatment for small cell lung cancer (SCLC) with brain metastases: a case report |
2021-11-01 |
10.1136/jitc-2021-sitc2021.632 |
Fan Jieqiong, Zhang Yao, Mo Xiaofei, Guo Jing |
| 764495 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
665 Transcriptional landscape of tumor-reactive TIL in lung cancer and melanoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.665 |
Zhang Jiajia, Caushi Justina, Zhang Boyang, Ji Zhicheng, Li Taibo, Ji Hongkai, Pardoll Andrew, Smith Kellie |
| 764494 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
434 Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.434 |
Evans Elizabeth, Fisher Terrence, Mallow Crystal, Foster Amber, Smith Ernest, Leonard John, Chaney Marya, Zauderer Maurice |
| 764493 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
664 Pulmonary priming of tumor-reactive CD8+ T cells by DC1 is impaired by regulatory T cells |
2021-11-01 |
10.1136/jitc-2021-sitc2021.664 |
Zagorulya Maria, Morgan Duncan, Yim Leon, Horton Brendan, Torres-Mejia Elen, Spranger Stefani |
| 764492 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
433 A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04 |
2021-11-01 |
10.1136/jitc-2021-sitc2021.433 |
Cirauqui Beatriz, Cohen Ezra, Keam Bhumsuk, Machiels Jean-Pascal, Oosting Sjoukje, Welliver Tim, Guan Shanhong, Jin Feng, Forgie Alison, Fanning Philip, Ruffner Katherine, Pons Jaume, Randolph Sophia, Harrington Kevin |
| 764491 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
432 Nemvaleukin alfa, a novel engineered IL-2 cytokine, in combination with the anti-PD-1 antibody pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma (ION-01 study) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.432 |
Gastman Brian, Cheever Mac, Fling Steven, Perez Cesar, Patel Manish, Geiger Jessica, Li Zujun, Posner Marshall, Steuer Conor, D’Amico Leonard, Kask Angela Shaulov, Du Yangchun, Matthies Derek, Huh Sung Jin, Wang Yan, Graham Julie, Chow Laura |
| 764490 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
431 First-in-human phase I clinical trial evaluating intraperitoneal administration of MOv19-BBz CAR T cells in patients with alpha folate receptor-expressing recurrent high grade serous ovarian cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.431 |
Shah Payal, Shlanksy-Goldberg Richard, Martin Lainie, Nadolski Gregory, Hexner Elizabeth, Shamimi-Noori Susan, Hwang Wei-Ting, Matlawski Tina, Cervini Amanda, Shea Joanne, Nelson Lauren, Lacey Simon, Plesa Gabriela, Lledo Lester, Dengel Karen, Marshall Amy, Leskowitz Rachel, Kandalaft Lana, Figini Mariangela, Canevari Silvana, Coukos George, Powell Daniel |
| 764489 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
427 Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study |
2021-11-01 |
10.1136/jitc-2021-sitc2021.427 |
Coward Jermaine, Frentzas Sophia, Mislang Anna, Gao Bo, Lemech Charlotte, Jin Xiaoping, Li Baiyong, Wang Max, Kwek Kon Yew, Zhou Yiting, Xia Yu |
